Praxis Precision Medicines, Inc. (PRAX) intrinsic value & 10-year financials
Praxis Precision Medicines, Inc. (PRAX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 249.5% a year to $0, with an average return on invested capital of -633.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $241.76
- Market cap
- $5.4B
- Revenue (FY2025)
- $0
- Revenue growth (8-yr CAGR)
- 249.5%
- ROIC (10-yr avg)
- -633.7%
- Free cash flow (FY2025)
- -$249.1M
PRAX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$303.3M | -$13.48 | -$249.1M | — | -86.9% |
| FY2024 | $8.6M | -$182.8M | -$10.21 | — | -2340.3% | -166.3% |
| FY2023 | $2.4M | -$123.3M | -$18.69 | -$111.2M | -5164.4% | -3666.8% |
| FY2022 | $0 | -$214.0M | -$4.64 | -$185.5M | — | -322.8% |
| FY2021 | — | -$167.1M | -$3.94 | -$125.6M | — | -314.4% |
| FY2020 | — | -$61.8M | -$7.86 | — | — | 92.3% |
| FY2019 | — | -$35.5M | — | -$33.5M | — | 28.5% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Praxis Precision Medicines, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Praxis Precision Medicines, Inc. has historically struggled to out-earn its cost of capital, averaging just -1.5% ROIC.
Praxis Precision Medicines, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Praxis Precision Medicines, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-447.75 per share.